Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a rare autosomal inherited skin blistering disorder caused by mutations in the type VII collagen gene (COL7A1). Bonafont et. al. reported an electroporation-based COL7A1 exon 80 deletion strategy for RDEB treatment, which efficiently restored functional type VII collagen (C7) in the RDEB patient keratinocyte cells (RDEBK)ex vivo. Following this strategy, we synthesized and tested a library of hyperbranched aminated polyesters (HAPEs) as gene delivery vectors and developed topical non-viral gene editing therapies for RDEB. The CRISPR/Cas9 machinery was delivered by the selected HAPEs in either an all-in-one plasmid or ribonucleoprotein complex (RNP) to cells. HAPE-D/DNA complexes achieved higher or comparable gene expression (96% positive cells), compared to commercial reagents including LipofectamineTM 3000, XfectTM, jetPEI®, and jetOPTIMUS®. Furthermore, CRISPR/Cas9 plasmid delivered by HAPE-D contributed to around 25% targeted deletion of COL7A1 exon 80 and bulk C7 restoration in RDEBK polyclones, while maintaining good cell viability. The best protein delivery HAPE (HAPE-P) demonstrated great ability on universal protein delivery and successfully delivered cytosolic protein such as bovine serum albumin, immunoglobulin, saporin and β-Galactosidase into HeLa and RDEBK cells. The cytosolic delivered β-Galactosidase had 5 times better enzymatic activity than commercial reagents like PULsin® and Pierce™ Protein Transfection Reagent in HeLa and RDEBK cells (P<0.0001). Complexed with HAPE-P, CRISPR Cas9 RNP introduced 69% indels and 32% targeted exon 80 deletion in human embryonic kidney polyclones. In summary, the newly developed HAPEs in this study can efficiently deliver a CRISPR/Cas9 system in either DNA or ribonucleoprotein format. The non-viral gene editing therapy developed here achieved efficient C7 restoration in RDEBK cells, which has a high potential for use as a topical treatment for RDEB and can be adapted to other diseases.

New options to manage epidermolysis bullosa

Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.

836 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using a Highly Branched Poly(β-Amino Ester) Polymer (HPAE-EB)

398 A Simple, Efficient Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial

CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

901 Non-viral Gene Editing Therapy for Recessive Dystrophic Epidermolysis Bullosa: CRISPR/Cas9 Mediated COL7A1 Exon 80 Deletion Strategy

834 CRISPR/Cas9 Based COL7A1 Genomic Editing in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Via Non-Viral Polymer Delivery System

455 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa: Hyper Branched Aminated Polyesters Mediated Minicircle DNA Delivery

Advances and Challenges in Gene Therapy for Dystrophic Epidermolysis Bullosa: Insights from Therapeutic Strategies and Animal Models

Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa

200 A Comparison of Minicircle Vectors Expressing COL7A1 under the Control of Human Promoters for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects

Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa

Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa

Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa

Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa

Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa

Efficient and Robust Highly Branched Poly(β-amino Ester)/minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes